Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Public ClinicalTrials.gov record NCT00483496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of the Protection Activity of Microfine Ti02, Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With SU: Phase II Photoprovocation Test
Study identification
- NCT ID
- NCT00483496
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Orfagen
- Industry
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209) Drug
- Ti02 pigmentary 3% alone (formula RV3131A-MV1211) Drug
- bisoctrizole 10% alone (formula RV3131A-MV1237) Drug
- Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213) Drug
- Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329) Drug
- Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212) Drug
- Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)] Drug
- V0096 CR vehicle (formula RV3131A-MV1197) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Dec 21, 2017
2007 – 2008
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Henry Ford Medical Center | Detroit | Michigan | 48202-2689 | — |
| St Luke's Roosevelt Hospital Center | New York | New York | 100025 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00483496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00483496 live on ClinicalTrials.gov.